Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May;32(5):1430-1439.
doi: 10.1111/jce.15004. Epub 2021 Apr 16.

Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis

Gabriela M Prado  1 , Felix Mahfoud  2 , Renato D Lopes  3 , Dalmo A R Moreira  1 , Rodolfo Staico  1 , Lucas P Damiani  4 , Christian Ukena  2 , Luciana V Armaganijan  1
Affiliations
Meta-Analysis

Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis

Gabriela M Prado et al. J Cardiovasc Electrophysiol. 2021 May.

Abstract

Introduction: Ventricular arrhythmias (VAs) are a major cause of morbidity and mortality in patients with heart disease. Recent studies evaluated the effect of renal denervation (RDN) on the occurrence of VAs. We conducted a systematic review and meta-analysis to determine the efficacy and safety of this procedure.

Methods and results: A systematic search of the literature was performed to identify studies that evaluated the use of RDN for the management of VAs. Primary outcomes were reduction in the number of VAs and implantable cardioverter-defibrillator (ICD) therapies. Secondary outcomes were changes in blood pressure and renal function. Ten studies (152 patients) were included in the meta-analysis. RDN was associated with a reduction in the number of VAs, antitachycardia pacing, ICD shocks, and overall ICD therapies of 3.53 events/patient/month (95% confidence interval [CI] = -5.48 to -1.57), 2.86 events/patient/month (95% CI = -4.09 to -1.63), 2.04 events/patient/month (95% CI = -2.12 to -1.97), and 2.68 events/patient/month (95% CI = -3.58 to -1.78), respectively. Periprocedural adverse events occurred in 1.23% of patients and no significant changes were seen in blood pressure or renal function.

Conclusions: In patients with refractory VAs, RDN was associated with a reduction in the number of VAs and ICD therapies, and was shown to be a safe procedure.

Keywords: ICD shocks; antitachycardia pacing; implantable cardioverter-defibrillator; renal denervation; ventricular arrhythmias.

PubMed Disclaimer

References

REFERENCES

    1. Huang B, Scherlag BJ, Yu L, Lu Z, He B, Jiang H. Renal sympathetic denervation for treatment of ventricular arrhythmias: a review on current experimental and clinical findings. Clin Res Cardiol. 2015;104:535-543.
    1. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-1017.
    1. Schwartz PJ. Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol. 2014;11:346-353.
    1. Linz D, Wirth K, Ukena C, et al. Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm. 2013;10:1525-1530.
    1. Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63-67.

LinkOut - more resources